Major Depressive Disorder: Fulfilling the Promise of Therapeutics

Bradley Neil Gaynes, MD, MPH

Disclosures

October 03, 2022

Bradley Neil Gaynes, MD, MPH, considers the assorted modes of treatment for major depressive disorder (MDD). By way of offering counsel to aspiring clinicians, Dr Gaynes observes the range of established MDD therapies, from the pharmacologic to the psychotherapeutic, noting that each will have greater or lesser applicability according to the specific patient/clinician dynamic.

Dr Gaynes goes on to suggest that this profusion of treatments achieves its full promise only when employed in a collaborative approach, where consultations with those both inside and outside the field serve to enhance the clinical encounter and maximize outcomes.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....